Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/1998

01-01-1998 | ORIGINAL ARTICLE

A novel glycoprotein obtained from Chlorella vulgaris strain CK22 shows antimetastatic immunopotentiation

Authors: K. Tanaka, Akira Yamada, Kiyoshi Noda, Takashi Hasegawa, Masao Okuda, Yukihiro Shoyama, Kikuo Nomoto

Published in: Cancer Immunology, Immunotherapy | Issue 6/1998

Login to get access
Metadata
Title
A novel glycoprotein obtained from Chlorella vulgaris strain CK22 shows antimetastatic immunopotentiation
Authors
K. Tanaka
Akira Yamada
Kiyoshi Noda
Takashi Hasegawa
Masao Okuda
Yukihiro Shoyama
Kikuo Nomoto
Publication date
01-01-1998
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050448

Other articles of this Issue 6/1998

Cancer Immunology, Immunotherapy 6/1998 Go to the issue

ORIGINAL ARTICLE

FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewisx hapten

ORIGINAL ARTICLE

Transforming growth factor β , (TGFβ) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon γ and tumor necrosis factor α reduces the production of active TGFβ

ORIGINAL ARTICLE

Immunogenicity of synthetic conjugates of Lewisy oligosaccharide with proteins in mice: towards the design of anticancer vaccines

ORIGINAL ARTICLE

Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine response

ORIGINAL ARTICLE

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

ORIGINAL ARTICLE

Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits